2024年6月24日 (一) 09:59的版本

Treatment of canine hemangiosarcoma: 2000 and beyond

https://doi.org/10.1892/0891-6640(2000)014%3C0479:tochab%3E2.3.co;2

1 摘要

犬血管肉瘤 （HSA） 是一种侵袭性恶性肿瘤，预后严重。手术和化疗在延长 HSA 狗的生存时间和提高生活质量方面的成功有限。肿瘤内科的进步正在提高兽医癌症患者的生存率和生活质量。对转移机制的理解导致了旨在延缓或抑制肿瘤扩散的新疗法的开发。有前途的新治疗选择包括新型给药系统（吸入或腔内化疗）;使用免疫调节剂，如脂质体封装的胞壁酰三肽-磷脂酰乙醇胺;抗转移药物，如血管生成抑制剂（干扰素、沙利度胺）、基质金属蛋白酶抑制剂和米诺环素;饮食调整;和基因治疗。血管生成抑制剂似乎是安全的，并且与传统化疗不同，不会引起耐药性。尽管许多较新的方法仍在开发和审查中，但使用结合创新治疗方式的多模式疗法可能为受 HSA 影响的狗提供最佳治疗选择。

Canine hemangiosarcoma (HSA) is an aggressive and malignant neoplasia with a grave prognosis. Surgery and chemotherapy have limited success in prolonging survival times and increasing quality of life in dogs with HSA. Advances in medical oncology are resulting in increased survival rates and a better quality of life for veterinary cancer patients. An understanding of mechanisms of metastasis has led to the development of new treatments designed to delay or inhibit tumor spread. Promising new treatment options include novel delivery systems (inhalation or intracavitary chemotherapy); use of immunomodulators such as liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine; antimetastatic agents such as inhibitors of angiogenesis (interferons, thalidomide), matrix metalloproteinase inhibitors, and minocycline; dietary modifications; and gene therapy. Inhibitors of angiogenesis seem to be safe and, unlike conventional chemotherapy, do not induce drug resistance. Although many of the newer approaches are still under development and review, the use of multimodality therapy incorporating innovative treatment modalities may offer the best therapeutic option for dogs affected with HSA.

2 Reference

• Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs 2014 阿霉素化疗治疗狗的推定性心脏血管肉瘤

• Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for HSA 2017 多柔比星-环磷酰胺与多柔比星-达卡巴肼辅助治疗犬血管肉瘤的比较